These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2572857)

  • 21. Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss.
    Breum L; Møller SE; Andersen T; Astrup A
    Int J Obes Relat Metab Disord; 1996 Feb; 20(2):147-53. PubMed ID: 8646251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
    Goodall E; Oxtoby C; Richards R; Watkinson G; Brown D; Silverstone T
    Br J Psychiatry; 1988 Aug; 153():208-13. PubMed ID: 2908235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug therapy after very-low-calorie diets.
    Finer N; Finer S; Naoumova RP
    Am J Clin Nutr; 1992 Jul; 56(1 Suppl):195S-198S. PubMed ID: 1615883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F; Lambert J; Rasio E; Serri O
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug therapy of obesity--results of treatment with dexfenfluramine].
    Ivković-Lazar T; Stokić E; Lepsanović L
    Med Pregl; 1990; 43(5-6):232-5. PubMed ID: 2287309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical studies with dexfenfluramine: from past to future.
    Guy-Grand B
    Obes Res; 1995 Nov; 3 Suppl 4():491S-496S. PubMed ID: 8697048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    Pfohl M; Luft D; Blomberg I; Schmülling RM
    Int J Obes Relat Metab Disord; 1994 Jun; 18(6):391-5. PubMed ID: 8081430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
    Stewart GO; Stein GR; Davis TM; Findlater P
    Med J Aust; 1993 Feb; 158(3):167-9. PubMed ID: 8450782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients.
    Kolanowski J; Younis LT; Vanbutsele R; Detry JM
    Eur J Clin Pharmacol; 1992; 42(6):599-605. PubMed ID: 1623900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical studies with d-fenfluramine.
    Guy-Grand B
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):173S-176S. PubMed ID: 1728829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy of fenfluramine in treatment of obesity.
    Douglas JG; Gough J; Preston PG; Frazer I; Haslett C; Chalmers SR; Munro JF
    Lancet; 1983 Feb; 1(8321):384-6. PubMed ID: 6130379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity.
    Ditschuneit HH; Flechtner-Mors M; Dolderer M; Fulda U; Ditschuneit H
    Horm Metab Res; 1993 Nov; 25(11):573-8. PubMed ID: 8288160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
    Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
    N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women.
    Andersson B; Zimmermann ME; Hedner T; Björntorp P
    Eur J Clin Pharmacol; 1991; 40(3):249-54. PubMed ID: 2060560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity.
    Stahl KA; Imperiale TF
    Arch Fam Med; 1993 Oct; 2(10):1033-8. PubMed ID: 8111484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
    Astrup A; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Larsen TM
    Lancet; 2008 Nov; 372(9653):1906-1913. PubMed ID: 18950853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.
    Drent ML; Adèr HJ; van der Veen EA
    J Endocrinol Invest; 1995 Nov; 18(10):780-8. PubMed ID: 8787955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.